TIFFANY PADILLA: Open Payments
NPI 1497765010 · LITTLE ROCK, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,230 in 113 payments from 21 companies in 2025. Trend: 2023 $1,795 · 2024 $1,422 · 2025 $2,230
Food & beverage: $2,133Education: $96
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 18 | $331 |
| GlaxoSmithKline, LLC. | 18 | $224 |
| Insmed, Inc. | 9 | $205 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 11 | $201 |
| GENZYME CORPORATION | 10 | $169 |
| Merck Sharp & Dohme LLC | 7 | $143 |
| United Therapeutics Corporation | 5 | $136 |
| Verona Pharma, Inc. | 5 | $110 |
| HARMONY BIOSCIENCES LLC | 4 | $100 |
| Regeneron Healthcare Solutions, Inc. | 4 | $92 |
Products named: DUPIXENT, FASENRA, Arikayce, OFEV, ZERBAXA, Tyvaso, TRELEGY ELLIPTA, NUCALA.
Industry payments across AR — which companies pay providers there.
